Form 4: Caribou Biosciences CEO Granted Significant Equity

Caribou Biosciences' President and CEO, Rachel E. Haurwitz, received significant equity grants including restricted stock units and stock options.

Summary

• Rachel E. Haurwitz, President and CEO of Caribou Biosciences, Inc. (CRBU), was granted 151,700 Restricted Stock Units (RSUs) on February 20, 2026.
• These RSUs will vest in four equal annual installments, commencing on February 20, 2027, contingent on continued service to the Issuer.
• An option to purchase 682,500 shares of Common Stock was also granted on February 20, 2026, with an exercise price of $1.8 per share.
• The stock option vests monthly, with 1/48 of the total shares vesting on each monthly anniversary of the grant date, becoming fully vested by February 20, 2030, subject to continued service.
• Following these transactions, Rachel E. Haurwitz directly beneficially owns 447,150 shares of Common Stock and indirectly owns 3,369,395 shares through The City Canyon Family Trust dated May 31, 2021.
• The reporting person has elected to use a durable sell-to-cover instruction to satisfy withholding tax obligations related to the February 20, 2026 vesting of previously-granted RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it strengthens the alignment of the CEO's interests with long-term shareholder value through significant equity grants, indicating continued commitment from leadership.

Positives

• The significant equity grants align the President and CEO's long-term financial interests with those of the shareholders, promoting sustained performance.
• The vesting schedules for both RSUs and stock options incentivize continued service and commitment to the company's strategic goals over several years.

Negatives

• The equity grants do not provide immediate liquidity to the CEO, as they are subject to multi-year vesting schedules.
• The value of these grants is dependent on the future performance of Caribou Biosciences' stock price, introducing market risk.

Risks

• Continued employment is a condition for the vesting of both the Restricted Stock Units and the stock options, meaning the awards could be forfeited if service ceases.
• The ultimate value realized from these equity awards is subject to the volatility and performance of Caribou Biosciences' common stock in the market.

Future Outlook

The equity grants provide a long-term incentive structure for the President and CEO, aligning her financial success with the company's future growth and shareholder value creation through 2030 and beyond.

Management Comments

• The reporting person has elected, consistent with the terms of a durable sell-to-cover instruction, to pay cash to satisfy withholding tax obligations due in connection with the February 20, 2026 vesting of previously-granted RSUs.

Industry Context

StockSavvy.ai notes that significant equity grants to executive leadership are a standard practice in the biotechnology sector, particularly for companies like Caribou Biosciences that are focused on long-term research and development. These grants are crucial for attracting and retaining top talent and ensuring executive incentives are aligned with the company's long-term strategic objectives and shareholder value creation.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options with multi-year vesting schedules, is a common and widely accepted practice across the biotech and broader technology industries to incentivize executive performance and retention.
• While the specific size of the grant would typically be benchmarked against peer companies of similar market capitalization and stage of development, the filing itself does not provide sufficient data for a direct comparative analysis of the grant's magnitude against specific comparable companies or projects.

Related Party Transactions

• Shares are held indirectly by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse.

Stakeholder Impact

• Shareholders: The grants align the CEO's interests with long-term shareholder value, potentially leading to more focused strategic decisions.
• Employees: The CEO's continued commitment and incentivization can foster stability and direction within the company.

Next Steps

• The RSUs will begin vesting in four equal annual installments starting February 20, 2027.
• The stock option will continue to vest monthly, becoming fully vested by February 20, 2030.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants, which aligns management's long-term interests with shareholders. It does not present new fundamental information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Caribou Biosciences, CRBU, Rachel Haurwitz, Form 4, SEC filing, equity grant, RSU, stock option, insider transaction, executive compensation, vesting